首页> 美国卫生研究院文献>AMIA Summits on Translational Science Proceedings >Using Similarity Metrics on Real World Data and Patient Treatment Pathways to Recommend the Next Treatment
【2h】

Using Similarity Metrics on Real World Data and Patient Treatment Pathways to Recommend the Next Treatment

机译:在现实世界的数据和患者治疗途径上使用相似性指标来推荐下次治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Non-small-cell lung cancer (NSCLC) is one of the most prevalent types of lung cancer and continues to have an ominous five year survival rate. Considerable work has been accomplished in analyzing the viability of the treatments offered to NSCLC patients; however, while many of these treatments have performed better over populations of diagnosed NSCLC patients, a specific treatment may not be the most effective therapy for a given patient. Coupling both patient similarity metrics using the Gower similarity metric and prior treatment knowledge, we were able to demonstrate how patient analytics can complement clinical efforts in recommending the next best treatment. Our retrospective and exploratory results indicate that a majority of patients are not recommended the best surviving therapy once they require a new therapy. This investigation lays the groundwork for treatment recommendation using analytics, but more investigation is required to analyze patient outcomes beyond survival.
机译:非小细胞肺癌(NSCLC)是最普遍的肺癌类型之一,并且五年生存率仍不高。在分析提供给非小细胞肺癌患者的治疗方法的可行性方面已经完成了大量工作。然而,尽管这些治疗方法中的许多方法在确诊的NSCLC患者群体中表现更好,但对于特定患者而言,特定治疗方法可能并不是最有效的治疗方法。使用Gower相似性度量标准和先前的治疗知识将患者相似性度量标准耦合在一起,我们能够证明患者分析如何在推荐次佳治疗方案时补充临床工作。我们的回顾性和探索性结果表明,大多数患者一旦需要新的治疗方法,便不被推荐为最佳生存方法。这项调查为使用分析方法推荐治疗奠定了基础,但是需要更多的调查来分析患者生存期以外的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号